A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity

Brooke L. Fridley, Gregory Jenkins, Daniel J Schaid, Liewei M Wang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Non-tumor cell-based model systems have recently gained interest in pharmacogenetic research as a hypothesis generating tool. The hypotheses generated from these model systems can be followed up in functional studies, or tested in individuals taking the same investigational agents. The current cellular phenotypes (e.g. cytotoxicity) of interest in these studies are based on the effects of an individual dosage of a drug on the cell lines, or a summary of results at many dosages of a drug (e.g. dose that inhibits 50 per cent of cell growth, GI50). A more complete analysis of the impact of genetic variation on all aspects of the dose-response curve may lend additional insight into the pharmacogenomics of a particular drug. This paper illustrates the use of a Bayesian hierarchical nonlinear model for the analysis of pharmacogenomic data with cytotoxicity endpoints. The model is illustrated with cytotoxicity and expression data collected on cell lines from a pharmacogenomic study of the drug gemcitabine. By completing an analysis based on the entire dose-response curve, we were able to detect additional genes that affect not only the GI50, but also the slope of the curve, which reflects the therapeutic index of the drug. Simulation studies also demonstrate that in comparison with the analyses based on the commonly used summary measure GI50, investigation of the impact of genetic variation on all aspects of the cytotoxicity dose-response curve is more informative, and more powerful with respect to detecting the effect of gene expression on cytotoxicity.

Original languageEnglish (US)
Pages (from-to)2709-2722
Number of pages14
JournalStatistics in Medicine
Volume28
Issue number21
DOIs
StatePublished - Sep 20 2009

Fingerprint

Genetic Variation
Cytotoxicity
Nonlinear Dynamics
Hierarchical Model
Nonlinear Model
Drugs
Dose-response Curve
Pharmaceutical Preparations
Pharmacogenetics
Cell
gemcitabine
Cell Line
Line
Phenotype
Gene Expression
Dose
Slope
Simulation Study
Entire
Model

Keywords

  • Cell lines
  • Cytotoxicity
  • Hierarchical nonlinear model
  • mRNA expression
  • Pharmacogenomics

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability

Cite this

A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity. / Fridley, Brooke L.; Jenkins, Gregory; Schaid, Daniel J; Wang, Liewei M.

In: Statistics in Medicine, Vol. 28, No. 21, 20.09.2009, p. 2709-2722.

Research output: Contribution to journalArticle

@article{56863f39f08840c79ae9e29ad7b7087a,
title = "A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity",
abstract = "Non-tumor cell-based model systems have recently gained interest in pharmacogenetic research as a hypothesis generating tool. The hypotheses generated from these model systems can be followed up in functional studies, or tested in individuals taking the same investigational agents. The current cellular phenotypes (e.g. cytotoxicity) of interest in these studies are based on the effects of an individual dosage of a drug on the cell lines, or a summary of results at many dosages of a drug (e.g. dose that inhibits 50 per cent of cell growth, GI50). A more complete analysis of the impact of genetic variation on all aspects of the dose-response curve may lend additional insight into the pharmacogenomics of a particular drug. This paper illustrates the use of a Bayesian hierarchical nonlinear model for the analysis of pharmacogenomic data with cytotoxicity endpoints. The model is illustrated with cytotoxicity and expression data collected on cell lines from a pharmacogenomic study of the drug gemcitabine. By completing an analysis based on the entire dose-response curve, we were able to detect additional genes that affect not only the GI50, but also the slope of the curve, which reflects the therapeutic index of the drug. Simulation studies also demonstrate that in comparison with the analyses based on the commonly used summary measure GI50, investigation of the impact of genetic variation on all aspects of the cytotoxicity dose-response curve is more informative, and more powerful with respect to detecting the effect of gene expression on cytotoxicity.",
keywords = "Cell lines, Cytotoxicity, Hierarchical nonlinear model, mRNA expression, Pharmacogenomics",
author = "Fridley, {Brooke L.} and Gregory Jenkins and Schaid, {Daniel J} and Wang, {Liewei M}",
year = "2009",
month = "9",
day = "20",
doi = "10.1002/sim.3649",
language = "English (US)",
volume = "28",
pages = "2709--2722",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "21",

}

TY - JOUR

T1 - A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity

AU - Fridley, Brooke L.

AU - Jenkins, Gregory

AU - Schaid, Daniel J

AU - Wang, Liewei M

PY - 2009/9/20

Y1 - 2009/9/20

N2 - Non-tumor cell-based model systems have recently gained interest in pharmacogenetic research as a hypothesis generating tool. The hypotheses generated from these model systems can be followed up in functional studies, or tested in individuals taking the same investigational agents. The current cellular phenotypes (e.g. cytotoxicity) of interest in these studies are based on the effects of an individual dosage of a drug on the cell lines, or a summary of results at many dosages of a drug (e.g. dose that inhibits 50 per cent of cell growth, GI50). A more complete analysis of the impact of genetic variation on all aspects of the dose-response curve may lend additional insight into the pharmacogenomics of a particular drug. This paper illustrates the use of a Bayesian hierarchical nonlinear model for the analysis of pharmacogenomic data with cytotoxicity endpoints. The model is illustrated with cytotoxicity and expression data collected on cell lines from a pharmacogenomic study of the drug gemcitabine. By completing an analysis based on the entire dose-response curve, we were able to detect additional genes that affect not only the GI50, but also the slope of the curve, which reflects the therapeutic index of the drug. Simulation studies also demonstrate that in comparison with the analyses based on the commonly used summary measure GI50, investigation of the impact of genetic variation on all aspects of the cytotoxicity dose-response curve is more informative, and more powerful with respect to detecting the effect of gene expression on cytotoxicity.

AB - Non-tumor cell-based model systems have recently gained interest in pharmacogenetic research as a hypothesis generating tool. The hypotheses generated from these model systems can be followed up in functional studies, or tested in individuals taking the same investigational agents. The current cellular phenotypes (e.g. cytotoxicity) of interest in these studies are based on the effects of an individual dosage of a drug on the cell lines, or a summary of results at many dosages of a drug (e.g. dose that inhibits 50 per cent of cell growth, GI50). A more complete analysis of the impact of genetic variation on all aspects of the dose-response curve may lend additional insight into the pharmacogenomics of a particular drug. This paper illustrates the use of a Bayesian hierarchical nonlinear model for the analysis of pharmacogenomic data with cytotoxicity endpoints. The model is illustrated with cytotoxicity and expression data collected on cell lines from a pharmacogenomic study of the drug gemcitabine. By completing an analysis based on the entire dose-response curve, we were able to detect additional genes that affect not only the GI50, but also the slope of the curve, which reflects the therapeutic index of the drug. Simulation studies also demonstrate that in comparison with the analyses based on the commonly used summary measure GI50, investigation of the impact of genetic variation on all aspects of the cytotoxicity dose-response curve is more informative, and more powerful with respect to detecting the effect of gene expression on cytotoxicity.

KW - Cell lines

KW - Cytotoxicity

KW - Hierarchical nonlinear model

KW - mRNA expression

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=70449435534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449435534&partnerID=8YFLogxK

U2 - 10.1002/sim.3649

DO - 10.1002/sim.3649

M3 - Article

C2 - 19572260

AN - SCOPUS:70449435534

VL - 28

SP - 2709

EP - 2722

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 21

ER -